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Abstract
The metastatic process is complex and remains a major obstacle in the management of colorectal cancer. To gain a better
insight into the pathology of metastasis, we investigated genomic aberrations in a large cohort of matched colorectal
cancer primaries and distant metastases from various sites by high resolution array comparative genomic hybridization. In
total, 62 primary colorectal cancers, and 68 matched metastases (22 liver, 11 lung, 12 ovary, 12 omentum, and 11 distant
lymph nodes) were analyzed. Public datasets were used for validation purposes. Metastases resemble their matched primary
tumors in the majority of the patients. This validates the significant overlap in chromosomal aberrations between primary
tumors and corresponding metastases observed previously. We observed 15 statistically significant different regions
between the primary tumors and their matched metastases, of which only one recurrent event in metastases was observed.
We conclude, based on detailed analysis and large independent datasets, that chromosomal copy number aberrations in
colorectal metastases resemble their primary counterparts, and differences are typically non-recurrent.
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Introduction
Metastatic disease is the principal event leading to death in
patients with colorectal cancer (CRC), yet our understanding of
the molecular events leading to metastasis is still incomplete. The
formation of metastases is a multistep process, in which malignant
cells disseminate from the primary tumor to colonize distant
organs [1,2].
A variety of genetic and epigenetic events that lead to loss of
function of tumor suppressor genes, such as APC, TP53 and
SMAD4 and gain of function of oncogenes like KRAS and MYC,
drive tumor cell behavior in a Darwinian selection process. Two
hypotheses aim to explain how tumor cells acquire the (epi)genetic
alterations that make them proficient to metastasize. The
‘‘traditional model’’ suggests that the metastatic process is
accompanied by a sequential accumulation of (epi)genetic
alterations [3]. Tumor cells pass through successive rounds of
clonal progression and the most malignant cancer cells acquire the
capacity to seed new colonies at distant sites [4]. An alternative
‘‘predestination’’ hypothesis, implies that the capacity to metasta-
size is largely determined by the mutant alleles that are acquired
relatively early during tumorigenesis [5]. Subsets of genetic
aberrations responsible for oncogenic transformation are also
involved in the metastatic progression. This model does not
question clonal selection or the accumulation of genetic alter-
ations, but does not place metastatic dissemination near the end of
tumor progression [6]. According to this model, primary tumors
that can and cannot metastasize will differ more in their biologic
features than primary tumors and their associated metastases.
Some studies aimed to unravel metastasis-associated genomic
alterations by comparing the genetic profile of metastases with
unmatched primary tumors [7,8]. This approach is of limited
value due to the heterogeneity between individuals in the genetic
profile of their tumors. There are other studies that use ‘matched’
primaries and metastasis, which however use small datasets [9,10].
These studies indicated that copy number patterns of metastatic
tumor cells are similar to that of the primary tumor. Recurrent
copy number aberrations in metastases were not independently
validated in large datasets. Since the publication by Stange et al.
[9], which reports such a recurrent aberration, the array
comparative genomic hybridization (array CGH) technique has
dramatically improved. The oligo array CGH technique used here
allows for a 20-fold higher spatial detection resolution, with also
the capability of detecting important focal aberrations [11–15]. In
order to improve our understanding of the biology behind the
metastatic process, we conducted such high resolution array CGH
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analysis on a large set of primary CRC and matched metastases of
various distant sites.
Materials and Methods
Ethics Statement
The two randomized clinical trials, CAIRO and CAIRO2, were
approved by the Committee on Human-Related Research
Arnhem – Nijmegen and by the local institutional review boards.
FFPE tissue of another 8 patients was collected from the tissue
archive of the Department of Pathology at the Radboud
University Nijmegen Medical Centre, which was approved by
the local review board. Approval by the local review boards has
been done centrally by Medisch Ethische Toetsingscommissie
(METC) Nijmegen. The written informed consent required for all
patients before study entry also included translational research on
tumor tissue.
Patients and Tumor Samples
Formalin-fixed paraffin-embedded (FFPE) tissue of surgically
resected primary tumor, matched distant metastasis and matched
normal colon, was obtained from 62 patients. For 6 patients, tissue
samples of two different metastatic sites were collected. Array
CGH power analysis shows that this sample size (130 tissue
specimens) yields an average power of 0.5 to 0.9 [16]. The 68
metastatic tissue specimens consisted of 22 liver metastases, 11
lung metastases, 12 ovarian metastases, 12 omental metastases,
and 11 distant lymph node metastases. The power for these
metastatic homing organs is only sufficient to identify the most
statistically significant genetic recurrences by array CGH [16].
Eighteen patients included in this study participated in the
CAIRO clinical trial [17] (CKTO 2002–07, Clinical Trials.gov;
NCT00312000) and 36 patients the CAIRO2 trial [18] (CKTO
2005–02, ClinTrials.gov; NCT00208546) of the Dutch Colorectal
Cancer Group (DCCG).
FFPE tissue of another 8 patients was collected from the tissue
archive of the Department of Pathology at the Radboud
University Nijmegen Medical Centre.
Clinical and Histopathological Parameters
The following clinical features were collected for each patient:
age, gender, site of the primary tumor, metachronous (.6 months
after initial diagnosis) or synchronous (# 6 months of initial
diagnosis) onset of metastases. The TNM classification (5th ed.)
[19] was used to describe the extent of cancer spread in terms of
invasion depth and lymph node stage. Tumors were histologically
classified using the World Health Organization guidelines [20]. A
tumor was considered to be of the mucinous type when at least
50% of the tumor volume consisted of mucin. Primary tumors
were graded into well, moderately and poorly differentiated
adenocarcinomas based on the part of poorest differentiation in
the tumor. The mismatch repair system (MMR) status was
determined by immunohistochemistry and microsatellite instabil-
ity (MSI) analysis [21]. Two out of 62 patients (3%) were MMR
positive, which is a representative incidence for patients with
advanced CRC [21]. Clinical and pathological parameters are
summarized in Table 1.
Chromosomal Copy Number Detection by Array CGH
and Data Preprocessing
The procedures for DNA isolation, labeling and hybridization
were described previously [22]. DNA was isolated from an area
containing at least 70% tumor cells. The 180K CGH arrays (Gene
Expression Omnibus (GEO) platform GPL8687 Agilent Technol-
ogies, Palo Alto, USA) cover 169.793 unique chromosomal
locations across the genome at ,17 kb intervals, enriched with
4548 additional oligonucleotides, located at 238 of the Cancer
Census genes. Array image analysis was performed and local
background was subtracted from the signal median intensities of
both tumor and normal DNA. The log2 tumor to normal ratio was
calculated in the statistical programming language R with
CGHcall [23] and was normalized against the median value of
the log2 ratios of all the oligonucleotides mapped to the March
2006 human reference sequence (NCBI36/hg18) on chromosome
1–22 and X.
The cellularity parameter in the CGHcall data analysis software
was set according to the estimates made by the pathologist
(I.D.N.). Further data interpretation and copy number aberration
(CNA) calling was done with Nexus Copy Number 6.0 software
(Biodiscovery, El Segundo, USA) using default settings, except for
the Segmentation Algorithm, which was set to ‘‘Rank’’. The CNA
calling cut-off value for gene copy number gain or loss was set to
0.2 and 20.2, and for amplifications or homozygous deletions this
Table 1. Baseline characteristics of the 62 patients included
in the analysis.
Patients n, (%)
(n =62)
Gender Male 33 (53%)
Female 29 (47%)
Age Median (range) 60 (34–77)
Site of primary tumour Colon 29 (47%)
Rectosigmoid 15 (24%)
Rectum 16 (26%)
Unknown 2 (3%)
Onset metastases Metachronous 30 (48%)
Synchronous 32 (52%)
Diameter Median (range) 40 (15–135)
Invasion depth T1-2 5 (8%)
T3 47 (76%)
T4 10 (16%)
Lymph node status N0 12 (19%)
N1 22 (35%)
N2 26 (42%)
Unknown 2 (3%)
Classification Adenocarcinoma 54 (87%)
Mucinous carcinoma 8 (13%)
Differentiation grade Well 3 (5%)
Moderate 35 (56%)
Poor 24 (39%)
MSI status dMMR 2 (3%)
pMMR 60 (97%)
Site of metastases Liver 22 (32%)
Lung 11 (16%)
Omental 12 (18%)
Ovarian 12 (18%)
Distant lymph node 11 (16%)
Abbreviations: MSI; microsatellite instability, dMMR; deficient mismatch repair
system, pMMR; proficient mismatch repair system.
doi:10.1371/journal.pone.0086833.t001
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cut-off value was set to 0.6 and 21.0, respectively (Figure 1). The
array CGH data can be accessed using GEO, under accession
number GSE38479.
Array CGH Data Analysis
Unsupervised hierarchical clustering analysis was performed in
R with the segmented data according to the same procedures as
Stange et al. [9]. The distance was calculated based on a
Spearman correlation (Figure 1). Copy number concordance of
the metastasis with the corresponding primary tumor was defined
as a percentage of the genome with the same copy number (gain,
loss or normal). Therefore base pair positions of copy number
overlap were determined by start and end positions of the
segments, which were detected by the segmentation algorithm
described above. To compare the tumors pairs, DNA copy
number ratios of the primary tumor were subtracted from the
corresponding metastases. GISTIC [24] within Nexus 6.0 was
used to identify genomic regions that are significantly amplified or
deleted across this combined sample set (Figure 1). Output
included those regions with a high corresponding G score,
indicative of either a high frequency of occurrence or a high
amplitude for several samples or a combination. The method
accounts for multiple-hypothesis testing using the false-discovery
rate (FDR), and a FDR below 0.05 was used as a level of
significance.
Detection of Chromosome 6q21 and 8q24.21 (MYC) Co-
amplification in Large Independent Cohorts of Primary
Colorectal Tumors
The presence of the co-amplification of chromosome 6q21 and
8q24.21 (MYC) was assessed in array CGH data of 542 primary
colorectal tumors. These array CGH profiles were derived from
349 primary colorectal tumors who participated in either the
CAIRO [17] or the CAIRO2 [18] study (JC Haan et al., in
preparation), and from 193 primary colorectal tumors present in
The Cancer Genome Atlas (TCGA). Chromosomal amplifications
were identified by CGHcall [23] for the CAIRO and CAIRO2
samples, and by cBio Cancer Genomics Portal (http://www.
cbioportal.org) [25] for the samples of the TCGA dataset, and
were only acknowledged if the log2 ratio of the segmented values
was higher than 2.
Fluorescence in situ Hybridization (FISH)
Copy number status of both chromosome 6q21 and 8q24.21
(MYC), as well as of the centromeres of chromosome 6 and 8 were
assessed by FISH analysis [26]. The MYC locus probe (8q24.12-
q24.13), 6q21 locus probe (start 106772738–106950984), and the
centromere probes of chromosome 6 (6p11.1-q11) and 8 (8p11.1-
q11.1) (Vysis, Abbott Molecular, Abbott Park, Illinois, USA).
Signals for each probe were counted in at least 40 cells per tumor
sample. Samples with a ratio greater than 3 between MYC or 6q21
versus the centromere signals, in 10% of cells or more, were scored
positive for amplification.
Results
Striking Similarity in DNA Copy Number Status between
Primaries and Matched Metastases
Patterns of DNA copy number aberrations between 62 primary
tumors and 68 matched metastases were highly similar for the
majority of the patients (Figure 2). When the group of primaries
was compared to the group of metastases, only gain of
chromosomes 2p25.3 and 2q21.3 were more frequently observed
in metastases (p,0.001; Table S1). However, after correction for
multiple testing no significant regions were left (FDR.0.05).
Cluster analysis revealed that DNA copy number profiles of
pairs are more similar to each other than between tumors of
different patients. For 6 patients, metastases and the corresponding
primary tumors were not joined pairwise in the cluster dendro-
gram (Figure 3). Histological re-evaluation showed similar
morphologies within each of these 6 matched pairs. Two of the
6 patients clustered with only one tumor or tumor pair between
them. The remaining 4 copy number profiles are shown in Figure
S1.
Non-recurrent Differences between Primaries and
Metastases of Individual Patients
Overall, a median of 27% of aberrant genome was detected in
primary tumors versus a median of 33% in the metastases. This
difference is not a consequence of tumor cell percentage which was
corrected for. We performed a pair wise comparison of the
metastases and the primary tumor per metastasis (Figure 4). This
comparison revealed 4 metastases with genomic overlap with the
primary tumor of gain, loss or normal DNA copy number of more
than 95% (median 96.8% (95.6–100%)). In addition, 43 metas-
Figure 1. Flowchart of data preprocessing and analysis procedures. In grey analysis performed in R, in white analysis performed in Nexus.
doi:10.1371/journal.pone.0086833.g001
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tases showed overlap between 70 and 95% (median 82.0% (72.0–
94.7%)), and the remaining 21 metasases had an overlap in of less
than 70% (median 60.3% (41.6–69.7%)) No specific metastatic site
was overrepresented in any of these groups. Three of the four
patients that did not join pairwise in the cluster analysis are in the
group of less than 70% overlap (53.4, 67.8 and 69.7%). The
remaining sample that did not cluster pairwise had an overlap of
82%.
To establish which genomic regions show overall differences in
copy number aberrations between the group of primary and
metastatic tumors we generated a combined dataset. The log2
values of the primary tumors were subtracted from the log2 values
of the metastases for each position (unique oligonucleotide on the
array) by GISTIC [24]. We observed 15 statistically significant
events with, 13 regions of lower DNA copy number ratios and 2
regions of higher DNA copy number ratios in the metastases
compared to the primary (Table S2). The significant GISTIC
peaks identified were due to a high log2 ratio of metastases versus
primary tumors (high level amplification)rather than a high
frequency, hence these are high amplifications in the metastases
rather than recurrent gains (or losses). One exception is a co-
amplification that we detected in 3 metastases of two patients(see
below).
The same approach revealed 7 regions with higher DNA
copy number ratio and 8 regions with lower DNA copy number
ratio in the 22 liver metastases compared to the primary tumor
(Table S3). In the 12 omental metastases 1 region showed a
higher copy number ratio and 5 regions lower copy number
ratio in comparison to the primary tumor (Table S4). In the
other metastatic organs (ovary, lung, and distant lymph nodes)
significant differences in DNA copy number ratios between
metastases and primary tumors were not observed.
Stange et al. [9], reports a difference at chromosome 11p15.5
in a study of 21 patients with liver metastases. Re-analysis of the
data according to our procedures described here, confirms the
11p15.5 gain in 6 liver metastases not present in the primary
tumors. On this array CGH platform 3 BAC clones are located
within this region. Neither in the 22 patients with liver
metastases nor in the remaining 40 patients with other
metastatic sites, gain of this region was detected, despite the
38 oligonucleotides located within this chromosomal region.
Two out of 62 patients (3%) were MSI (patient 18 and 30). The
percentages of genomic overlap of copy number aberrations
between the primary tumors and their metastasis in our MSI
patients were 88% and 96% respectively. Moreover the primary
tumor and the metastases of these patients clustered next to
each other. Due to the low incidence of MSI tumors in our
study population, this does not affect the conclusions of our
study, neither we can conclude anything about this subtype
because of low sample size.
Figure 2. Frequency plots of DNA copy number aberrations in 62 primary tumors and 68 matched metastases. (A) Frequencies of
aberrations based on called data for primary tumors and (B) metastases. The x-axis displays clones spotted on the array sorted by chromosomal
position. The y-axis displays the frequency of tumors with gains (above zero) or losses (below zero). Boundaries of chromosomes are indicated by
dotted lines.
doi:10.1371/journal.pone.0086833.g002
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A Co-amplification only Observed in Metastasis Including
the MYC Oncogene
In only two patients we observed a recurrent high level co-
amplification in the metastases, which was not detected in the
primary tumor. The co-amplification is located at 6q21 and
8q24.21, the latter encompassing the MYC oncogene. Respectively
16 and 19 genes are located on these regions listed in Table S2.
One of these patients had two metastatic sites involved, both
harboring this co-amplification (Figure 5). These array CGH
results were confirmed by FISH analysis showing high level
amplifications of MYC and chromosome 6q21 (Figure 6). The co-
amplification did not result from translocation, since no co-
localization was observed by FISH. Moreover we did not observe
subclones with high level amplification of MYC or chromosome
6q21 alone.
We analyzed copy number profiles of 349 primary colorectal
tumors of the CAIRO studies and 193 primary colorectal tumors
of the Cancer Genome Atlas Network [27]. We detected high level
amplification ofMYC, once in the CAIRO and 3 times in the Atlas
datasets. Amplification at 6q21 was once detected only in the
CAIRO datasets. The co-amplification was not observed in these
542 primary tumors.
Discussion
Primary tumors and their metastases are genetically highly
similar. Therefore, we reason that many chromosomal aberrations
arise in the primary tumor before metastatic spread. In the past
years, genetic data have become available that support the idea
that the metastatic behavior seems to be predetermined relatively
early in tumorigenesis. First, micrometastases are observed in
many individuals with small, low-stage tumors [28]. Second, RNA
expression profiling of the bulk of primary tumors predict the
metastatic recurrence of cancer patients [29,30]. Third, micro-
array analysis revealed that RNA expression and DNA copy
number patterns of metastatic tumor cells were strikingly similar to
that of the primary tumor [9,10,31]. Sequence analysis of coding
regions in primary and metastatic tumor genomes also suggest that
only a few mutations are required to transform cells from an
invasive colorectal tumor into cells that have the capability to
metastasize [32]. Genome wide sequencing of matched primary
and metastatic tissues has only been performed in small patient
cohorts. In the study of Kloosterman et al. [33], significant overlap
in somatic structural changes between 4 primary tumors and their
corresponding metastases was observed. Moreover, whole-genome
sequencing of matched primary pancreatic tumors and metastases
[34], and genomic analyses of primary prostate cancer and
metastases [35] revealed highly similar genomic profiles in these
solid malignancies as well. This suggests that essential mutations
and chromosomal aberrations required for cancer progression
would occur in the primary tumor before initiation of the
metastatic spread.
Nevertheless, differences are observed in DNA copy numbers
between primaries and metastases, for which several potential
scenarios are possible. Either genetic changes occur because the
primary and metastasis are different branches from a common yet
heterogeneous ancestor [36], or changes occur after dissemination.
We hypothesize that the most likely scenario is a combination of
both heterogeneity within the primary tumor and post-dissemina-
tion effects. It is thereby important to take into account that
chromosomal aberrations in less than 30% of tumor cells can go
undetected with arrays [37]. Since a primary colorectal tumor can
be quite large and only a small cross section was taken for copy
number analysis, heterogeneity would be reflected in the copy
Figure 3. Dendrogram of unsupervised hierarchical clustering
of DNA copy number aberrations of all tumors. All tumors
includes 62 primary CRC tumors (p) and 68 matched metastases (m).
The numbers and pointers on the left show the patients of which the
primary tumor and metastasis did not cluster together.
doi:10.1371/journal.pone.0086833.g003
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number measurements and explain some of the differences
between matched primaries and metastases. Another explanation
for the observed differences could be that the studied metastasis
arose from a distinct primary. Some of the patients included in our
cohort presented with metachronous metastases and consequently
received (neo)adjuvant systemic treatment. The effect of systemic
treatment on chromosomal instability however is largely unknown,
but probably limited since no recurrences were identified and no
significantly increased number of gene variants (associated with
pathways relevant in cancer) were observed as a result of
chemotherapy [38]. Our data strengthen this observation because
the patients who did receive (neo)adjuvant systemic treatment
clustered pairwise. None of the 6 patients who did not cluster
together received chemotherapy and targeted agents.
Stange et al. [9] published a dataset of 21 paired samples where
a characteristic gain was found in 6 of 21 liver metastases (29%) on
Figure 4. Genomic overlap of primary tumors (p) and matched metastasis (m). (A–B) Example of a tumor metastasis pair from the group
with less than 70% genomic overlap of gain, loss or normal DNA copy number (total 20 patients of which 3 patients were not joined pairwise in the
dendrogram of Figure 3)and (C–D) example of a tumor metastasis pair from the group with 70 and 95% genomic overlap of gain, loss or normal DNA
copy number (38 patients of which 1 patient was not joined pairwise in the dendrogram of Figure 3) The x-axis displays clones spotted on the array
sorted by chromosomal position. The y-axis displays the log2 ratios of the clones. The segments are depicted by grey lines. Boundaries of
chromosomes are indicated by dotted lines. (E) Histogram of the percentages of genomic overlap of gain, loss or normal DNA copy number of all
tumor metastasis pairs. The x-axis displays the percentages of overlap. Tthe y-axis displays the frequencies of the metastases.
doi:10.1371/journal.pone.0086833.g004
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chromosome band 11p15.5 that was observed in only 1 primary
tumor (5%). They confirm this observation in an independent
dataset of liver metastases (n = 50, 30% gain). The Cancer
Genome Atlas Network recently reported that one of the most
common focal gains is at 11p15.5 in 7% of primary CRC tumors
[27]. In our dataset we observe ca. 10% gain of the same region
without a significant difference between both primary and
metastasis (Figure 2). Thus although we could confirm a same
frequency of gain in the primary tumors, we were not able to
confirm a higher frequency in our set of patients with liver
metastases (n = 22), nor in other metastatic sites. We conclude that
(focal) gain at 11p15.5 is not prevalent for metastasis in our
dataset, as opposed to the reported findings by Stange et al. [9].
We only observed one recurrent event; two patients with co-
amplifications on the same chromosomal locations in the
metastases, which were not present in the primary tumor. This
co-amplification was not detected previously in larger series of
primary tumors, nor in smaller studies of metastases. Previous
series of metastases did not use high resolution array CGH, and
may thus have missed this focal co-amplification. Hence, the
Figure 5. DNA copy number profiles of metastases containing a co-amplification at chromosome 8q24.21 and 6q21. DNA copy
number profiles of two patients containing a co-amplification of at 8q24.21 (MYC) and chromosome 6q21 in the metastasis (B, D, E), which was not
present in the primary tumor (A, C). The x-axis displays clones spotted on the array sorted by chromosomal position. The y-axis displays the log2 ratios
of the clones. The segments are depicted by grey lines. Boundaries of chromosomes are indicated by dotted lines.
doi:10.1371/journal.pone.0086833.g005
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association of this specific co-amplification with metastasis needs
further confirmation by high resolution copy number analysis on a
large series of CRC metastasis. In the era of personalized anti-
cancer treatment it is essential to understand the diverging features
between primaries and metastases and which tissue will best
predict treatment outcome. Current clinical practice is to use
archived material of the primary tumor to determine molecular
aberrations and mutations to select patients for treatment, whereas
in fact therapy is oriented towards treating the metastases. Since
genomic profiles are highly similar between the primary tumor
and the metastasis this approach is now justified and it is unlikely
that precursor cells of overt metastases in CRC disseminate early
to sites where they proceed to undergo their own divergent genetic
evolution.
Array Data Availability
GEO accession number GSE38479.
Token:
http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token= fjaflewyayqeapw&acc =GSE38479.
Supporting Information
Figure S1 DNA copy number profiles. DNA copy number
profiles of patients of which the correlation of the primary tumor
(p) and their metastasis (m) was substantially low with more than
one tumor pair between them. The patients showed genomic
overlap of gain, loss or normal DNA copy number of (A–B) 67.8%,
(C–D) 82.0%, (E–F) 69.7% and (G–H) 53.4%. The x-axis displays
clones spotted on the array sorted by chromosomal position. The
y-axis displays the log2 ratios of the clones. The segments are
depicted by grey lines. Boundaries of chromosomes are indicated
by dotted lines.
(TIFF)
Figure 6. FISH analysis confirming high level co-amplification of MYC (8q24.21) and chromosome 6q21. FISH analysis confirming high
level co-amplification of MYC (8q24.21) and chromosome 6q21 in metastatic tissue (lymph node, sample m45) which were absent in the matched
primary tumor (sample p45). (A) Primary tumor without the MYC amplification (red probe: MYC (8q24.21), green probe: centromere chromosome 8).
(B) Distant lymph node metastasis with the MYC (8q24.21) amplification (red probe: MYC (8q24.21), green probe: centromere chromosome 8, gain).
(C) Primary tumor without the chromosome 6q21 amplification (green probe: 6q21, red probe: centromere chromosome 6). (D) Distant lymph node
metastasis with the 6q21 amplification (green probe: 6q21). (E) Co-amplification of MYC (8q24.21) and chromosome 6q21 in a distant lymph node
(red probe: MYC, green probe: 6q21). Abbreviations: CEP6; centromere chromosome 6, CEP8; centromere chromosome 8.
doi:10.1371/journal.pone.0086833.g006
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Table S1 Comparison of frequencies of DNA copy
number aberrations between the primary tumors and
the metastases. Abbreviations: FDR; false discovery rate.
(DOC)
Table S2 GISTIC approach in combined samples.
*Regions which overlap with the results of liver metastasis, **
Regions which overlap with the results of omental metastases.
Abbreviations: FDR; false discovery rate.
(DOC)
Table S3 GISTIC approach in combined samples of
liver metastasis. Abbreviations: FDR; false discovery rate.
(DOC)
Table S4 GISTIC approach in combined samples of
omental metastasis. Abbreviations: FDR; false discovery rate.
(DOC)
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